Top Markets
Coin of the day
Lisata Therapeutics, Inc. Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

LSTA
Pozycja w akcjach #32451
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on... Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Cena akcji
$1.11
Kapitalizacja rynkowa
$10.06M
Zmiana (1 dzień)
1.38%
Zmiana (1 rok)
-56.32%
Kraj
US
Handel Lisata Therapeutics, Inc. (LSTA)

Kategoria

Historia ceny akcji dla Lisata Therapeutics, Inc. (LSTA)
Najwyższa cena zamknięcia: $1.12 dnia 2026-08-01

Najniższa cena zamknięcia: $188.93K dnia 1999-03-01
Historia cen akcji firmy Lisata Therapeutics, Inc. od 1999 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 52.31%
2025 -28.03%
2024 3.05%
2023 -6.25%
2022 -78.23%
2021 -42.33%
2020 -36.52%
2019 -44.38%
2018 26.19%
2017 2.72%
2016 -70.04%
2015 -68.59%
2014 -44.74%
2013 2.99%
2012 11.54%
2011 -61.50%
2010 -9.12%
2009 147.46%
2008 -61.79%
2007 -75.15%
2006 19.82%
2005 -7.65%
2004 -69.11%
2003 253.51%
2002 -86.70%
2001 -26.92%
2000 -63.97%
1999 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$515.58 31.26%
US
$992.01 51.72%
NL
$736.64 7.19%
CH
$1.07K -6.40%
KR
$255.50 13.38%
BE